Logo
x

Search

Subscribe Now

P-III Trial

GC Publishes the Results of GC5107 in P-III Trial for the Treatment of Primary Immunodeficiency in Frontiers in Immunology

GC Publishes the Results of GC5107 in P-III Trial for the Treatment of Primary Immunodeficiency in Frontiers in Immunology

  • August 12, 2021
AstraZeneca Reports Results of AZD1222 in Primary Analysis of P-III Trial for the Prevention of COVID-19

AstraZeneca Reports Results of AZD1222 in Primary Analysis of P-III Trial for the Prevention of COVID-19

  • March 25, 2021
EirGenix Report Results of EG12014 (biosimilar- trastuzumab) in P-III Trial for HER2-Positive Breast Cancer

EirGenix Report Results of EG12014 (biosimilar- trastuzumab) in P-III Trial for HER2-Positive Breast Cancer

  • March 25, 2021
Regeneron Reports Results of REGEN-COV Antibody Cocktail in P-III Trial to Prevent COVID-19

Regeneron Reports Results of REGEN-COV Antibody Cocktail in P-III Trial to Prevent COVID-19

  • March 23, 2021
GSK and Medicago Initiate P-III Trial for Adjuvanted COVID-19 Vaccine Candidate

GSK and Medicago Initiate P-III Trial for Adjuvanted COVID-19 Vaccine Candidate

  • March 17, 2021
AstraZeneca's Imfinzi Fails to Meet its Primary Endpoints in P-III KESTREL Study

AstraZeneca's Imfinzi Fails to Meet its Primary Endpoints in P-III KESTREL Study

  • February 8, 2021
Boan Biotech Reports the Completion of Patient Enrolment in the P-III Clinical Trial of BA5101, a Proposed Biosimilar Dulaglutide

    Boan Biotech Reports the Completion of Patient Enrolment in the P-III Clinical Trial of BA5101, a Proposed Biosimilar Dulaglutide

    • May 15, 2023
    Samsung Bioepis Reports P-III Trial Results of SB3 (biosimilar, trastuzumab) for HER2-Positive Breast Cancer

      Samsung Bioepis Reports P-III Trial Results of SB3 (biosimilar, trastuzumab) for HER2-Positive Breast Cancer

      • May 8, 2023
      Amolyt Pharma to Initiate P-III Clinical Trial of Eneboparatide for the Treatment of Hypoparathyroidism

        Amolyt Pharma to Initiate P-III Clinical Trial of Eneboparatide for the Treatment of Hypoparathyroidism

        • May 3, 2023
        Celltrion Reports 24 Week P-III Trial Results of CT-P42 (biosimilar, aflibercept) for Wet Age-Related Macular Degeneration and Diabetic Macular Edema

          Celltrion Reports 24 Week P-III Trial Results of CT-P42 (biosimilar, aflibercept) for Wet Age-Related Macular Degeneration and Dia...

          • April 3, 2023
          Regeneron Presents P-III Trial Results of Dupixent (dupilumab) for Atopic Hand and Foot Dermatitis at AAD 2023

            Regeneron Presents P-III Trial Results of Dupixent (dupilumab) for Atopic Hand and Foot Dermatitis at AAD 2023

            • March 20, 2023
            Harbour BioMed Reports P-III Trial Results of Batoclimab for the Treatment of Generalized Myasthenia Gravis

              Harbour BioMed Reports P-III Trial Results of Batoclimab for the Treatment of Generalized Myasthenia Gravis

              • March 6, 2023
              Image

              Incisive News in 3 Shots.

              Contact Us

              Our Information

              Follow Us

              Copyright © 2025 PharmaShots - All Rights Reserved.